Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2017

Is Necitumumab an Effective Addition To
Traditional Chemotherapeutic Regiments When
Treating Stage IV Lung and Colon Cancer?
J. Ross Hosford
Philadelphia College of Osteopathic Medicine

Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Oncology Commons
Recommended Citation
Hosford, J. Ross, "Is Necitumumab an Effective Addition To Traditional Chemotherapeutic Regiments When Treating Stage IV Lung
and Colon Cancer?" (2017). PCOM Physician Assistant Studies Student Scholarship. 384.
https://digitalcommons.pcom.edu/pa_systematic_reviews/384

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Is Necitumumab an effective addition to
traditional chemotherapeutic regiments when
treating stage IV lung and colon cancer?

J. Ross Hosford, PA-S
A SELECTIE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirement for the Degree of Master of
Science in Health Sciences- Physician Assistant

Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania, USA

16 December 2016

ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
Necitumumab is an effective add on treatment to traditional chemotherapy regimes when treating
stage IV lung or colon cancer.
Study Designs: Review of two open label, randomized, controlled phase III trials and one single
arm multicenter phase II study.
Outcomes Measured: Objective tumor response rate was measured for patients with colon
cancer. Overall survival rate and length of survival were measured for patients with lung cancer.
This was measured in Kapler Meier Methodology.
Results: For two trials the addition of Necitumumab improved overall survival and tumor
response rate. The first lung cancer trial did not show improvement of survival rate with
Necitumumab. In this trial those receiving the experimental drug had a median survival of 11.3
months compared to 11.5 in those not receiving the experimental medicine. The second lung
cancer trial saw survival times as 11.5 months with Necitumumab compared to 9.9 months
without it. In the third trial all patients were given Necitumumab in addition to FOLFOX agents
for colon cancer. Tumor response rate was compared between those with a KRAS wildtype gene
mutation and those with a KRAS mutant gene mutation. The results showed a higher tumor
response rate for those with the wildtype mutation, however both groups saw positive reduction
in tumors.
Conclusion: The addition of Necitumumab to traditional chemotherapy regimes is an effective
way to fight stage IV cancer, especially in those with a KRAS wildtype mutation or with
squamous non-small cell lung cancer. It is less effective for non-squamous non-small cell lung
cancer.
Key Words: Lung Cancer, Colon Cancer, Necitumumab, Stage IV, metastasis, chemotherapy
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INTRODUCTION
Stage IV cancer is often a grave diagnosis for patients. It conjures thoughts of suffering,
radiation, and weight loss. As clinicians we must take great care in how we approach managing
care for these patients. Optimizing quality of life, managing expectations, and trying our best to
fight the spread of tumors are among our goals. Treatment options range from chemotherapy and
radiation to surgical excision. An entire field of medicine has been created to fight cancer and we
now have fantastic treatment centers and talented specialists across the country. Despite this
when a patient presents for the first time and is diagnosed with late stage disease it is extremely
rare to see a full recovery. At this stage of the disease our focus is often on prolonging the
patients time with us and assuring they maintain a high quality of life while going through
treatment. For this reason there are ever evolving chemotherapy regiments being researched and
put into trial.
This paper aims to discuss three separate of such chemotherapy trials. The drug in
question is called Necitumumab. It is an epithelial growth factor receptor monoclonal antibody.
This drug seeks to bind to protein growth factors expressed in tumors and target them for
destruction by our immune system. It is a novel medicine because previous chemotherapeutic
agents were created using a combination of mouse and human DNA. Necitumumab is created
using only human DNA, thus increasing the chance that our bodies will recognize it as “self” and
allow it to bind to tumors more effectively2. The new medicine is being manufactured under the
brand name Portrazza.
The topic of treating late stage cancer is extremely relevant to the practice of Physician
Assistants across our country. Not only is Oncology a massive area of research and clinical
practice, PA’s are playing an increasingly important role in this specialty. They possess all of the
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clinical tools needed to be an effective part of an Oncology team. In 2013 there were 212,584
new cases of lung cancer in this country and 156,176 deaths from this disease6. Costs associated
with a diagnosis like this are astronomical. Some estimates put the costs as high as 90,000 per
patient in order to get treatment1. It is for these reasons that finding more effective and efficient
ways to handle late stage cancer is relevant both to PAs and for the medical community in
general.
Research into this disease is extensive. It is thought that the origins of tumors are in
defective gene expression and the cell cycle. Malignant tumors are pieces of tissue which
essentially have rapid cell turnover resulting in an imbalance between cell creation and cell
death. This leads to tumor growth and masses forming within the body. The mechanics of tumor
growth have their origins in genetics. There are several contributing factors which add to the
development of either lung or colon cancer. The leading cause of lung cancer is tobacco smoke.
There are massive scale campaigns across the world to encourage smoking cessation and prevent
youth from starting the habit. It is often thought that a contributing factor to colon cancer is the
“Western diet”. This is a diet high in carbohydrates and low in insoluble fiber4. Nutrition
campaigns seek to educate the public on the importance of eating a balanced diet not only for the
reason of nutritional sufficiency, but also as a preventive measure for serious diseases such as
colon cancer.
Treatment regiments for cancer include chemotherapy, radiation, surgical excision, or a
combination of all three. It is the judgement call of the clinical team and the patient as to which
combination of treatment will be most beneficial. Chemotherapy for lung cancer almost always
includes a platinum agent such as Cisplatin and one other additional medication. For squamous
cell lung cancer Gemcitibine is usually added while for non-squamous cell Pemetrexed is the
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additional agent of choice. Colon cancer has been shown to respond best to FOLFOX agents4.
Portrazza is being proposed as a new agent of add-on treatment because of it is made using only
human DNA and is thought to be more effective in activating our immune system to attack tumor
cells.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not Portrazza is an
effective add on treatment to traditional chemotherapy regiments when treating stage IV lung or
colon cancer.
The populations studied in these trials were composed of individuals over the age of 18
who had histologically confirmed squamous non-small cell, non-squamous non-small cell, or
colorectal carcinoma. All individuals in the trials had to have either late stage (III or IV) or
metastatic disease. The intervention used on these patients was adding Portrazza to their
chemotherapy regime. For the trials involving pulmonary structures average time of survival
after initiation of treatment was the measured outcome. This was measured using Kaplin Meier
methodology. Comparisons in these studies were between two groups of people; one group
received traditional chemotherapy combinations while the other group received the same
combination with the addition of Portrazza. These were both open label, randomized, controlled
phase III trials8,9. For the study involving structures of the lower GI tract the outcome measured
was objective tumor response rate. This was measured using the Response Evaluation Criteria in
Solid Tumors, Version 1.0. All member of this trial received Portrazza in addition to FOLFOX
agents. The comparison was between one group which had a KRAS wildtype gene mutation and
another group which had a KRAS mutant gene mutation. This was a single arm, multicenter,
phase II study3.
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Key words used in searches were “lung cancer”, “colon cancer”, “Portrazza”,
“chemotherapy”, and “stage IV”. All articles were published in American English. They were
searched on PubMed and Cochrane Library Collection and selected based on their clinical
relevance to PAs and whether they included patient oriented outcomes. All articles were
published and the research was done by the author of this paper. Inclusion/ exclusion criteria is
included on Table 1. Statistics used include ARR, RRR, NNT, p-value, and confidence intervals.
Demographic information from the trials is included in Table 1.
Table 1
Study

Type

Elez, E,
Hendlisz, A,
Delaunoit,
T.
(2016)3

Single arm
multicenter
phase II
study

Thatcher, N,
Hirsch, FR,
Luft.
(2015)9

Open label,
randomized
controlled
phase 3
trial.

# of
pts
25

w/
d
0

Age

Inclusion criteria

>18

Advanced
unresectable or
metastatic
adenocarcinoma
of the colon or
rectum, life
expectancy > 6
months, an
Eastern
Cooperative
Oncology Group
performance
status < 2,
adequate organ
function.

1093

77

>18

Adequate organ
function of 0-2
as defined by the
Eastern
Cooperative
Oncology.
Availability of
archived tumor
tissue for the
analysis of
biomarkers.

Exclusion
criteria
Prior systemic
chemotherapy
for locally
advanced
unresectable
CRC, prior
radiotherapy
to >25% of
bone marrow,
documented
or
symptomatic
brain
metastasis

Intervention

Previous
chemotherapy
within 4
weeks of trial.
Chest
irritation
within 12
weeks of the
trial. Brain
metastasis

Addition of
Necitumumab
to
Gemcitibine
and Cisplatin.

Addition of
Necitumumab
to FOLFOX6
agents.
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Paz-Ares L,
Mezger J,
Ciuleanu
TE.
(2015)8

Open label
randomized
controlled
phase 3
trial.

633

54

>18

No previous
chemotherapy,
adequate organ
function,
measurable
disease as
defined by
RECIST 1.0
criteria,
histologically
confirmed stage
IV cancer.

Brain
metastasis,
third-space
fluid
retention,
peripheral
neuropathy
grade 2 or
worse, major
surgery
therapy within
4 weeks prior.

Addition of
Necitumumab
to Pemetrexed
and Cisplatin.

RESULTS
In the trial composed by Paz- Ares, et al, there was not sufficient evidence to support the
use of Portrazza as a more effective treatment for late stage lung cancer. In this trial 315 patients
received the experimental combination of medicine (Portrazza, Cisplatin, and Pemetrexed) while
318 received the traditional chemotherapy regiment (Cisplatin and Pemetrexed). Unfortunately,
the results were not promising, as the authors remark, “there was no significant difference in
overall survival between treatment groups”8. The median survival of the experimental group was
11.3 months while median survival of the group receiving traditional therapy was 11.5 months.
P-value in this study was 0.968. Data was still collected between the two groups and results are
recorded in Table 2. The average survival time was not the only factor which was measured.
Mortality rate at one year was also measured and this showed that the experimental group
actually had a lower rate than the control. Based on the mortality rate at one year the relative risk
reduction of the experiment group was 11% while the absolute risk reduction was 2.5%. There
were 79 participants in the experimental group still living after one year compared to 72 of the
control group. The numbers needed to treat in this experiment was 40, meaning 40 patients
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would need to receive the experimental medicine in order to attain one more beneficial outcome.
The CER and EER were measured based on the number of patients who were still living after
one year.
Further trials for this medicine were warranted and are discussed later in this paper.
Despite the difference in average survival times in first trial it is important to note that the
authors do feel that their data is still useful. An important factor in this trial is that the histology
of disease being treated was non-squamous non-small cell lung cancer while in the following
trial patients with squamous non-small cell were being treated. It is possible that one type of cell
is more responsive to the experimental treatment than other types.
Table 2
Control

Experimental

Relative

Absolute

Numbers

95%Confidence

Event Rate

Event Rate

Risk

Risk

Needed

Interval

(CER)
22.6%

(EER)
25.1%

Reduction
11%

Reduction
2.5%

to Treat
40

Control 43-54%
Exp. 42-53%

In the trial conducted by Thatcher, et al, the authors again had two sample groups. The
first group had 545 patients who received Portrazza in addition to Gemcitabine and Cisplatin.
The second group had 548 patients and received only Gemcitabine and Cisplatin. The results
were more promising in this study. Authors concluded that “the addition of Necitumumab to
Gemcitabine and Cisplatin chemotherapy improves overall survival in patients…and represents a
new first line treatment option for this disease”9. The average survival time in the control group
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was 9.9 months compared to 11.5 months in the experimental group. As with the first trial the
data calculated in this paper was based not on the average survival time, but on the number of
deaths measured at one year into the experiment. Again the experimental group came out on top
with better survival rates. The relative risk reduction for this trial was 21%. Absolute risk
reduction was 4%. The number needed to treat was 25, meaning that 25 patients would need to
be treated in order for one additional beneficial outcome to be obtained. P-value when measuring
average time of survival was 0.019. It is safe to say that the numbers display a benefit in using the
experimental medicine. There were 127 patients living at one year in the experimental group
compared to 106 in the control group. Table 3 summarizes this data. The event measured for
EER and CER in the table was number of patients alive after one year.
Table 3
Control Event Experimental

Relative Risk

Absolute

Numbers 95% Confidence

Rate (CER)

Event Rate

Reduction

Risk

Needed

(EER)

(RRR)

Reduction

to Treat

21%

(ARR)
4%

25

19%

23%

Interval

Control 13-20%
Exp. 16-24%

The third trial for this medication, performed by Elez, et al, was designed differently than
the first two. It was a single arm phase II study and rather than investigating lung cancer the
experimental and control groups had stage IV colorectal cancer. All patients in this trial received
Portrazza in addition to FOLFOX6 chemotherapy. One variable which the designers of this trial
were aiming to measure is whether or not certain genetic mutations in humans are more

Hosford, Novel Chemotherapeutics 8
responsive to Portrazza than others. This is useful because as we advance research into cancer
treatment we may be able to tailor medication to the specific patient and their genetic makeup.
The results of this trial demonstrated that those who had the KRAS wild type gene mutation had
better outcomes than those who had a KRAS mutant gene mutation3. For the purpose of data
collection in this trail the experimental group consists of patients with the wild type gene
mutation and those in the control group had the mutant type mutation. Total experimental
participants were 16 patients and the total control group was 9 patients.
The results show that those with the wild type mutation had a better partial response rate.
10 members of the trial receiving with the wild type mutation had a partial response rate
compared to 5 members who had the mutant type mutation. This rate is what was measured to
obtain the values in table 4. The control event rate was 55% and experimental event rate was
62.5%. The relative benefit increase was 12.6% and the absolute benefit increase was 7.0%. The
numbers needed to treat was 14, meaning 14 patients needed to be treated to obtain one
additional favorable outcome. P-value was not reported in this study but the confidence interval
for the experimental group was 79-100% and for the control group was 66-100%3.
Table 4
Control

Experimental

Relative

Absolute

Numbers

95% Confidence

Event Rate

Event Rate

Benefit

Benefit

Needed

Interval

Increase

Increase

to Treat

12.6%

7.0%

14

55%

62.5%

Control 66-100%
Exp. 79-100%
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There are a number of adverse side effects of Portrazza which the authors of these studies
measured. In particular, the first two trials, which examined non-small cell lung cancer, measured
the rates of a grade 3 rash in their participants. These rates were used to then calculate the
numbers needed to harm for both of the clinical trials. In the trial by Paz Ares, et al, 44 members
of the experimental group developed a rash compared to only one member of the control group8.
The control event rate was .00314, experimental event rate was .140, and absolute risk increase .
136. Numbers needed to harm for this study was 7, meaning for every 7 patients treated with
Portrazza, one more will be affected by an adverse reaction. For the trial performed by Thatcher,
et al, 38 members of the experimental group developed a grade 3 rash compared with only two
members of the control9. The control event rate was .00365, experimental event rate was .07, and
absolute benefit increase .067. The numbers needed to harm was 15, meaning 15 patients would
need to be treated for one additional patient to have an adverse reaction of a grade 3 rash. This
data is summarized in Table 5.
Table 5
Control Event

Experimental

Absolute Risk

Numbers

Rate (CER)

Event Rate

Increase (ARI)

Needed to Harm

(EER)

(NNH)

Paz-Ares8

.00314

.140

.136

7

Thatcher, N9

.00365

.07

.067

15

Discussion
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This systematic review investigated two randomized control trials and one single arm
phase II study. The results were for the most part encouraging. Overall the addition of Portrazza
to a traditional chemotherapy increased percentage of living patients after one year and two years
of treatment. It also demonstrated that patients with different genetic mutations may be more
responsive to treatment with this medication. There were no obvious outliers in these studies.
Sample size and drop-out rates are two factors which limited these clinical trials. Given
the high rate of cancer diagnoses in the US it would be useful to have more trials with bigger
pools of participants in the future. Additionally, a number of group members in each trial
dropped out due to adverse drug reactions from the experimental medicine. This lowered the
sample size. The trial measuring treatment of colon cancer was limited in both size and
geographic location. The sample groups were very small and were taken in Europe where
lifestyle and diet can both have different effects on the body when compared to American
culture. Despite any short comings of these trials Portrazza was approved by the FDA in 2015 for
use in squamous non-small cell lung cancer7.
Portrazza is currently manufactured for an 800mg dose given intravenously over 60
minutes. For a three week cycle of therapy it is to be given on days 1 and 8. Though the most
common side effect is a rash there is a warning with this product that cardiopulmonary arrest and
hypomagnesemia are both potential adverse effects5. This is due to some patients experiencing
these in the clinical trials. One of the trials in this paper discussed using Portrazza in colorectal
cancer however it is currently only marketed for use is in squamous non-small cell lung cancer.
Pregnant women are advised against taking Portrazza. There are no studies in regards to breast
feeding while on this medication, but women are advised against doing this until at least three
months after their last dose5. There are no studies regarding using Portrazza in the pediatric
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population. There is currently no evidence that poor hepatic or renal function would be
contraindications to taking this medication. There is a risk of venous thromboembolism with
Portrazza. Manufacturers recommend discontinuing the medication immediately if patients
develop an embolism5.
Conclusion
The data collected in these three trials indicates that yes, Portrazza is effective in treating
Stage IV metastatic cancer. There is however a catch. It is only effective in squamous non-small
cell lung cancer. Two of the trials were performed on other types of cancer, and the medication
did not prove effective in prolonging life in non-squamous non-small cell. There is conclusive
evidence that those with a KRAS wildtype gene mutation may have a better outcome using
Portrazza than those who do not. Future studies may be more effective if they include patients
who have earlier stages of the disease. This could help tell us the efficacy of fully curing patients.
In the last few decades we have seen massive strides in research behind the pathophysiology of
cancer, treatments of this disease, and more effective ways of managing patient care. Portrazza is
another step in the right direction in our fight against this tragic disease.
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